Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments

Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally symptomatic prostate cancer. In this review we address the background of prostate cancer incidence and other available therapy on...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shilpa, Carballido, Estrella, Fishman, Mayer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143908/
https://www.ncbi.nlm.nih.gov/pubmed/21792315
http://dx.doi.org/10.2147/OTT.S14107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143908/
https://www.ncbi.nlm.nih.gov/pubmed/21792315
http://dx.doi.org/10.2147/OTT.S14107

Ejemplares similares